Overview of Небидо

Quick Facts

Property	Description
Active ingredient	Testosterone undecanoate
Form	Oily solution for injection
Pharmacological class	Androgen / Sex hormone preparation
Common use	Hormone replacement therapy (TRT)
Origin	Synthetic ester

What Type of Medicine is Небидо?

Небидо (Nebido) is a prescription-only medicine and a highly specialized Testosterone preparation. It is classified as an androgen and a sex hormone preparation, with the active ingredient being Testosterone undecanoate. This substance belongs to the ATC group G03BA03. This designation confirms the drug's role in replacing the body’s deficient endogenous hormone, Testosterone. The compound itself is a unique synthetic ester derivative of natural Testosterone, specifically engineered to enable its extended duration of action in the body.

Composition and Depot Form

The formulation of Небидо is defined by its method of delivery: an oily solution administered via deep intramuscular injection. This single-component product (monotherapy) contains the Testosterone undecanoate dissolved in an oily vehicle, typically castor oil. This high lipophilicity is a distinctive compositional feature that allows the injection to form a stable, localized reserve known as a depot formulation within the muscle. The subsequent slow and sustained release of the active ingredient from this depot is a defining characteristic of Небидо, minimizing the need for frequent dosing compared to other androgen preparations.

General Purpose of the Testosterone Derivative

The primary purpose of Небидо is to perform Testosterone replacement therapy (TRT) in adult males diagnosed with androgen deficiency, clinically known as hypogonadism. This treatment is indicated for conditions resulting from the absence of or deficiency in endogenous testosterone. The overall benefit of this long-acting treatment is the highly consistent stabilization of the patient's endocrine system action, which is clinically recognized as the key to effective hormonal management.

What side effects are possible with Небидо?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Testosterone undecanoate (Небидо) as classified by governmental regulatory authorities like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

The safety profile is structured by categorizing events based on their frequency and the body system affected.

Official Frequency Classifications

Classification	Examples of Associated Regulatory Events
Common (Affecting 1 to 10 users in 100)	Increase in red blood cell count (Polycythemia), increase in haematocrit and haemoglobin, weight increase, acne, headache, hot flush, increase in Prostate-Specific Antigen (PSA), prostate enlargement (BPH), and injection site reactions.
Uncommon (Affecting 1 to 10 users in 1,000)	Hypersensitivity reactions, depression, dizziness, hypertension, diarrhea, abnormal liver function tests, gynecomastia, and urinary retention.

Serious Adverse Reactions and Key Safety Constraints

Regulatory documents highlight specific serious conditions and limitations. Reactions such as Pulmonary Oil Microembolism (POME), characterized by symptoms like cough or dyspnea, are documented as rare events occurring during or immediately following the injection procedure due to the oily vehicle. The potential for the development or exacerbation of Sleep Apnea is also a recognized risk.

Use is strictly contraindicated in males with known or suspected prostate carcinoma or male breast cancer.

Specific safety considerations exist for older males (65 and over) due to the documented increase in risk for prostatic events, requiring regular monitoring of the prostate and PSA levels. As treatment progresses, effects such as Polycythemia and changes in PSA are associated with long-term exposure, necessitating periodic laboratory monitoring of blood parameters, liver function, and cholesterol levels.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Небидо overdose focuses on documented clinical signs indicative of excessively high serum testosterone concentrations. These manifestations of androgen excess include changes in disposition such as irritability and nervousness, as well as weight gain, and the genital manifestation of long-lasting or frequent erections (priapism). An elevated red blood cell count (polycythaemia) is a recognized laboratory finding associated with overexposure.

Urgent medical attention is required for any of these documented manifestations or if severe, life-threatening symptoms occur. High-dose testosterone exposure (abuse) is officially linked to serious outcomes, including cerebrovascular accident (stroke) and cardiac arrest.

The official management approach is procedural, as no specific antidote is known to reverse the effects of overdosage. The required regulatory action is the immediate termination of therapy or dose reduction, followed by symptomatic and supportive care to manage the resulting clinical signs. Continuous monitoring of serum testosterone concentrations is required to guide the management plan.

Therapeutic Uses of Небидо

What Небидо Treats: Main Uses and Benefits

The primary role of Небидо (Testosterone Undecanoate) is to act as a foundational Hormone Replacement Therapy (TRT) in adult males to treat established hypogonadism, a condition characterized by a deficiency or absence of endogenous testosterone. This therapy is generally indicated when testosterone deficiency is confirmed by both clinical features and biochemical tests.

Symptom Management and Therapeutic Focus

This medication is used as TRT to address symptoms related to systemic imbalance, helping to ease the overall symptom load associated with deficiency. The treatment is commonly used to help with symptom clusters that interfere with daily functioning, including symptoms related to physical discomfort, sexual function, and low mood. The long-acting formulation generally supports consistent endocrine stabilization, which is critical for the long-term management of this chronic deficiency state.

Quick Fact: Relief for Key Symptom Patterns
Sexual Symptoms	May assist with easing distress related to sexual symptoms.
Physical Manifestations	May assist with managing symptoms related to physical discomfort, such as fatigue and muscle changes.
Mood and Energy	Is relevant for easing distressing symptoms of low mood and irritability.

Eligibility and Restrictions for Use

Eligibility to use Небидо (Testosterone Undecanoate) is strictly defined by regulatory documentation and applies only to adult men with confirmed male hypogonadism (testosterone deficiency verified by clinical features and two separate blood tests).

Contraindicated Populations (Must Not Use)

Classification	Population/Condition	Restriction
Absolute	Women (including pregnant or breastfeeding)	Prohibited from use.
Absolute	Men with androgen-dependent carcinoma (prostate or male breast cancer)	Forbidden from use.
Absolute	Men with a past or present history of liver tumors (benign or malignant)	Forbidden from use.
Absolute	Patients with known hypersensitivity to the active substance or excipients	Prohibited from use.

Restricted or Conditional Use

Age-Related Rules: The medicine is not indicated for children and adolescents (males under 18 years) as its safety and efficacy are not established in this population. For the elderly population (over 65), there is limited experience regarding safety and efficacy.

Organ Dysfunction: Caution is required for patients with severe cardiac, hepatic, or renal insufficiency due to the risk of fluid retention; treatment must be stopped immediately if severe complications (e.g., congestive heart failure) occur. The FDA and EMA labels also advise caution for men with uncontrolled hypertension or risk factors for venous thromboembolism.

What should I know about interactions with other medicines?

The official interaction profile of Небидо (Testosterone undecanoate) is defined by several required monitoring and procedural constraints documented in regulatory labeling. The medicine may interact with coumarin-derived oral anticoagulants by increasing their activity, which carries an increased potential for bleeding. This pharmacodynamic effect mandates close and frequent monitoring of the patient's International Normalized Ratio (INR) and prothrombin time, particularly at the initiation or conclusion of the treatment period.

A second key interaction involves Corticosteroids and ACTH. Co-administration with these agents may enhance fluid retention (oedema), necessitating careful use, especially in populations with pre-existing cardiac, renal, or hepatic disease. For patients receiving antidiabetic agents, the co-administration of this androgen may decrease blood glucose and consequently decrease the requirements for insulin or oral hypoglycemic medications.

The regulatory profile also notes that medicines classified as enzyme inducers may potentially lead to increased clearance of the medicine. Furthermore, a strict administration rule states that the oily solution must not be mixed with any other medicinal product in the syringe due to compatibility constraints. Androgens may also interfere with laboratory results by decreasing thyroxine-binding globulin levels, though the free thyroid hormone levels are officially reported as unchanged.

Mechanism of Action

Nebido (testosterone undecanoate) is an inactive ester that initiates its pharmacological action through conversion to the endogenous hormone, testosterone. Following intramuscular administration, the compound forms a localized depot, or reservoir. Cleavage of the undecanoate ester by plasma esterases mediates the slow, gradual release of active, unbound testosterone into the circulation, leading to sustained serum concentrations.

The released testosterone acts as an agonist, diffusing into target cells where it binds to the intracellular Androgen Receptor (AR). The activated AR dimer complex translocates to the cell nucleus, where it binds to specific DNA sequences known as Hormone Response Elements (HREs). This interaction regulates gene transcription, modifying the expression of various proteins. The ensuing intracellular consequences include the modification of broad anabolic and metabolic signaling sequences. These pathways alter nitrogen retention and influence the expression of mediators related to bone remodeling and erythropoiesis, thus contributing to the systemic modulation of male physiological characteristics.

Dosage and Administration Information

Nebido (testosterone undecanoate) is administered as a long-acting, deep intramuscular injection for testosterone replacement therapy in men diagnosed with hypogonadism. This medication is exclusively for intramuscular use and must be administered by a healthcare professional.

Administration and Dosage Schedule

The standard protocol involves a 1000 mg (4 ml) injection. The injection must be administered very slowly to minimize risks, and the preferred site is the gluteus medius muscle to ensure proper deep intramuscular delivery.

Injection Event	Time from First Dose	Dosage (1000 mg/4 ml)
Initiation	Baseline	1 vial/ampoule
Loading Dose	6 weeks later	1 vial/ampoule
Maintenance	Every 10 to 14 weeks	1 vial/ampoule

Monitoring and Dose Adjustment

The injection interval for maintenance is typically every 10 to 14 weeks, but the exact timing should be individualized based on clinical symptoms and measured serum testosterone concentrations. Blood levels are usually monitored at the end of the dosing interval.

Shorter Interval: If testosterone levels fall below the normal range, the interval between injections may be shortened.
Longer Interval: If testosterone levels are too high, the injection interval may be extended, but should remain within the recommended range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Небидо

This overview summarizes the scientific studies and research patterns available for the active ingredient, Testosterone Undecanoate. It focuses on the types of evidence that exist, the populations studied, and the main areas of scientific uncertainty, consistent with regulatory documentation.

Evidence for Use in Symptomatic Male Hypogonadism

Clinical research exploring the primary use of this injection in Testosterone Replacement Therapy (TRT) includes both short-term Randomized Controlled Trials (RCTs) and extensive long-term observational studies. These studies was studied for its role in addressing the hormone deficiency in adult men diagnosed with hypogonadism.

Researchers primarily monitored research exploring biomarker changes, specifically whether it could achieve and sustain Total Testosterone levels within the normal, defined range. Studies monitored sustained Total Testosterone levels over the observation period. Research examined patient-reported outcomes related to subjective symptoms like sexual function and mood. However, research suggests that because outcomes reflecting daily functioning are reported by patients, findings were mixed across some shorter controlled trials, reflecting challenges in measuring these experiences reliably.

Evidence on Systemic Outcomes: Bone and Metabolic Health

Research has been studied for the medicine's association with indicators of bone health and metabolic parameters. Studies research examined changes in metabolic markers such as blood sugar and lipid profiles, and studies explored the effect on Bone Mineral Density (BMD). The evidence often comes from long-term observational settings and meta-analyses.

What Remains Uncertain in the Research Landscape

While an established body of evidence exists, the research landscape still contains areas of scientific uncertainty where data are still emerging or evidence is limited.

Long-Term Effects: For certain critical outcomes, such as definitive evidence on fracture event reduction or long-term cardiovascular outcomes, long-term effects are not fully established through large-scale, dedicated RCTs.
Generalizability: Sample sizes were modest in some specific trials, meaning the research does not determine whether an individual will respond similarly to the group findings.

Frequently Asked Questions (FAQ)

Common questions about Небидо (FAQ)

Q: How is Небидо different from the gels or patches?

According to official product information, Небидо is delivered as an oily solution for deep intramuscular injection forming a depot in the muscle. The defining characteristic is that the medicine is released slowly and steadily over a period of many weeks, which is the main difference compared to testosterone gels or patches that must be applied every day or two.

Q: How quickly does Небидо start working after the first injection?

Since Небидо is a long-acting injection designed for sustained release, the time it takes to reach stable levels is not immediate. To support the establishment of stable (adequate) testosterone levels, a second injection is often scheduled after six weeks, with subsequent injections spaced further apart.

Q: What is the longest time Небидо can be detected in the body?

Regulatory documents indicate the maintenance dosing interval for Небидо is typically between 10 to 14 weeks to keep testosterone concentrations stable. Blood levels are monitored near the end of this period to confirm they remain adequate.

Q: Is Небидо a steroid used for bodybuilding?

Official patient information clearly states that this medicine is not suitable for building muscles in healthy individuals or for increasing physical strength. It is an androgen replacement therapy intended only for men with a diagnosed medical condition involving testosterone deficiency.

Q: What happens if a scheduled injection is slightly delayed?

Official guidance emphasizes that consistency is important for maintaining stable testosterone levels. If the timing must be adjusted, a healthcare provider typically reviews serum testosterone concentrations and clinical symptoms.

Q: What is the difference between Небидо and injectable testosterone propionate?

Небидо contains the testosterone undecanoate ester. This chemical structure is what allows the medicine to be stored in a depot within the muscle, leading to a much longer release profile and the extended dosing schedule of 10 to 14 weeks. This differs significantly from other testosterone esters which may require much more frequent injections.

Q: Can a patient stop using Небидо suddenly?

In cases of severe medical complications, such as the development of congestive heart failure due to underlying cardiac, hepatic, or renal insufficiency, official guidelines state that the treatment should be stopped immediately by a healthcare provider. For other circumstances, any decision to discontinue treatment should involve consultation with a healthcare provider.

Q: Is there research evidence on using Небидо in people with kidney issues?

Official labeling advises that caution is required when using this medicine in patients with severe renal (kidney) insufficiency because they may have an increased risk of fluid retention (oedema). Formal studies have not been performed in patients with severe renal impairment.

Q: What is the main safety warning associated with Небидо?

The most serious warning specifically related to the injection procedure is the risk of Pulmonary Oil Microembolism (POME) reactions, which are rare but occur during or immediately following the injection. A patient is advised to contact their healthcare provider immediately if they experience symptoms like coughing, dizziness, or shortness of breath.

Q: What should a patient look for regarding signs of an adverse reaction?

Official product information advises contacting a healthcare provider for signs of a blood clot (e.g., painful swelling in a leg, sudden shortness of breath) or a POME reaction (e.g., sudden coughing, feeling dizzy, chest pain). Your healthcare provider will also monitor for common effects like increased blood cell count.

Q: Do different countries have different indications for Небидо use?

The general purpose of Небидо is consistently indicated for testosterone replacement therapy in male hypogonadism across major regulatory jurisdictions (e.g., EU and US). While the core indication remains the same, specific dosing cautions and packaging details may vary between regional regulatory documents.

Q: Are there any known drug-drug interactions with supplements like St. John's Wort?

Yes. Official documents note that medicines classified as enzyme inducers may potentially speed up the clearance of testosterone undecanoate from the body, which could affect its effectiveness. This class of agents includes certain herbal remedies, such as St. John's Wort.

Q: Is it common to feel tired after the injection?

Official product safety documents list tiredness (fatigue) as an uncommon potential side effect, meaning it may affect up to 10 users in every 1,000. If fatigue is persistent or severe, this experience is typically managed by a healthcare provider.

Q: Are there specific vitamins or supplements that interact with Небидо?

Regulatory documents define a category of drugs known as enzyme inducers that can increase the rate at which the body clears the medicine. It is generally necessary to inform a healthcare provider about all drugs and supplements being taken, as this allows for proper management.

Q: Is hair loss a possible side effect of Небидо?

Yes, official safety information lists hair loss (alopecia) as an uncommon (infrequent) potential side effect. As with any side effect, the incidence and severity vary between individuals.

Q: Is a pre-filled syringe the only way Небидо is administered?

Official product information refers to Небидо being supplied in an ampoule or vial as an oily solution. A healthcare professional then draws the solution and administers it via a deep intramuscular injection.

Q: Does official prescribing information warn about aggression or irritability?

Yes, regulatory safety documents list irritability and aggression as uncommon (infrequent) potential side effects. These effects are related to the central nervous system (CNS) and are generally monitored by a healthcare provider if experienced.

Q: Are there any specific driving restrictions mentioned in relation to Небидо?

Official product information indicates that the medicine has no effect on the ability to drive and use machines. However, if side effects like dizziness are experienced, caution with activities like driving is generally advised.

Q: Is Небидо a controlled substance?

In the United States, testosterone undecanoate, the active ingredient in Небидо, is classified by the Food and Drug Administration (FDA) as a Controlled Substance, Schedule CIII. This designation indicates that the substance has accepted medical use but also potential for misuse.

Q: Is Небидо known to affect fertility in men?

Official product information notes that testosterone replacement therapy may cause a reversible decrease in sperm production (spermatogenesis), especially when high doses are administered. This is a known effect of administering external testosterone.

How should Небидо be stored and disposed of?

Storage Conditions

The official labeling for Nebido (testosterone undecanoate) states that no special storage conditions are required for the product. However, the medicine must be kept out of the sight and reach of children.

Since it is an oily solution, if it has been stored at a cold temperature, it should be brought to room or body temperature before use to ensure proper consistency for the injection.

Classification	Regulatory Requirement
Temperature	No special storage conditions required.
Stability	Must be used immediately after first opening.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Nebido is supplied in a single-use vial or ampoule. Consequently, any remaining unused solution must be discarded after the required dose is administered.

Disposal of any unused product or waste material must be carried out in accordance with local requirements for medicinal products, as this is intended to help protect the environment.

Небидо